News

Fierce Biotech19m
Amgen rolls out ph. 3 dosing plan for lead obesity candidate after midstage trial sees high discontinuation, vomiting rates
While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...
Ozempic and Mounjaro have new competitor as trial sees people lose 20% of body weight in one year
The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...
STAT19h
Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
What’s Happening With Amgen Stock?
Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...
New once-a-month drug could treat diabetes and obesity, scientists say
New once-a-month drug could treat diabetes and obesity, scientists say - Researchers say experimental drug’s less frequent ...
Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update
Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...
Devdiscourse17h
Amgen Unveils MariTide's Mixed Mid-Stage Results Amid Market Concerns
Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...
Healio17h
Once-monthly dosing of novel GLP-1 agonist/GIP antagonist yields substantial weight loss
Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...